Prolactinomas are the most common hormone-secreting pituitary tumours. Clinical symptoms result from effects
od hyperprolactinemia and from mass effects of the tumour expansion. Dopamine agonists are the treatment of choice.
Cabergolin (CAB) is preffered over bromocriptine (BRC) because of its high efficacy and good tolerability profile. Recent
data indicate that CAB is a safe choice even for women desiring pregnancy. Management of giant, agressive and resistant
prolactinomas still remains a challenge. Nowadays, medical treatment is the first therapeutic option, leaving neurosurgery
for complicated, resistant and malignant cases, possibly amplified by irradiation and temozolomid as useful